Seeking Alpha: Alzheimer's Drug Bapi Looks Done (Again)

Denial and bargaining are integral parts of the Kübler-Ross grief hypothesis, and anybody who writes about the healthcare and biotech sectors knows that Elisabeth Kübler-Ross was on to something. When I last wrote about the disappointing results of bapineuzumab (or bapi), a drug that Pfizer (PFE), Johnson & Johnson (JNJ), and Elan (ELN) were developing for Alzheimer's disease, I suggested that the drug was a goner and investors should respond accordingly.

Please continue here:
Alzheimer's Drug Bapi Looks Done (Again)